December 3, 2024 11:12 AM EST
Deals

Re­lay li­cens­es can­cer drug to Ko­re­an biotech for $75M

Elizabeth Cairns

Senior biopharma journalist

Re­lay Ther­a­peu­tics said last year it would de­lay the reg­u­la­to­ry fil­ing of li­rafu­gra­tinib in bile duct can­cer. Now it’s step­ping away from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times